AHZ is clearly NOT breaking out anywhere.
without better earnings guidance AHZ could suffer a decline. Maybe AHZ manufacturing and marketing Cardiocel is the wrong approach. There's something wrong here with AHZ sp. The market will lose patience with a company who've only signed up a handful of surgeons. Say what you like about the efficacy of the patch, but so far it's small time stuff.
